Objectives: The aim of this study was to evaluate the validity of partial CPITN (PCPITN) and full-mouth CPITN (FCPITN) indexes from CPITN index versions used in the diagnosis of periodontal disease. Method: The study included 1,000 patients over the age of 20. The clinical attachment loss examination and clinically assisted full-mouth periodontal examination (gold standard) including the depth of the periodontal pocket on probing and dental stones were performed. PCPITN and FCPITN index versions were compared with the gold standard oral examination. Sensitivity, specificity and diagnostic estimation tables were statistically created from the obtained data. Results: For Gingivitis, the sensitivity of the PCPITN index was found to be 68.88%, specificity was 85.94% and the field value under the Receiver Operating Characteristic (ROC) curve was 0.6893. For periodontitis, FCPITN index sensitivity was 89.28%, specificity was 96.56% and field value under the ROC curve was 0.931. Conclusion: Although FCPITN and PCPITN indexes have a near moderate value in the diagnosis of gingivitis, they were found to be more effective in the diagnosis of periodontitis. We think that the FCPITN index is particularly effective in the diagnosis of periodontitis. How to cite this article: Tanık A, Gül M. The validity of the Community Periodontal Index of Treatment Needs (CPITN) in Epidemiological Studies of Periodontal Diseases. Int Dent Res 2020;10(2):44-48. https://doi.org/10.5577/intdentres.2020.vol10.no2.3 Linguistic Revision: The English in this manuscript has been checked by at least two professional editors, both native speakers of English.
1 January 2019 in Biotechnology & Biotechnological Equipment
This study aimed at determining the oral and dental health and periodontal condition of adult patients in southeastern Turkey. Nine thousand and five hundred patients aged of 18–79 were included in the study. Demographic characteristics and education level of individuals were recorded. The Community Periodontal Index of Treatment Needs (CPITN) was used for periodontal status. According to the World Health Organization criteria, the Decayed, Missing and Filled Tooth (DMFT) index was used. The collected data were analyzed statistically. The average DMFT values of individuals were 6.72 ± 4.21. There was a statistically significant difference between DMFT value and, CPITN scores, depending on gender, age and education level (p < 0.001). According to the CPITN and DMFT indices, males had a 1.39-fold (95% CI: 1.33–1.45) and 1.01-fold (95% CI: 1.00–1.02) greater risk of gingival and dental health problems than females, respectively. Periodontal disease prevalence and DMFT values were determined to be high for those at older ages (57–69 age group) and low levels of education. It was also found that the oral health of males was worse than that of females.
18 February 2020 in İstanbul Tıp Fakültesi Dergisi
Background/aim: Caffeic acid phenethyl ester (CAPE) and Ankaferd Blood Stopper (ABS) are considered to contribute to wound healing. The purpose of this study was to investigate the effect of ABS and CAPE on secondary wound healing of oral mucosal tissue. Materials and methods: In total, 63 male Sprague-Dawley rats were used in this study. The animals were randomly divided into three groups and anaesthetized with ketamine (8 mg/100 g, intraperitoneally): a control group, CAPE group, and ABS group. A full-thickness excisional wound was created using a 4 mm punch biopsy tool. Topical ABS and CAPE were then applied in each group for 7, 14, and 21 days (n = 7 in each group). The animals in each group were sacrificed after 7, 14, and 21 days. Palatal specimens were stained with haematoxylin-eosin. Vascular endothelial growth factor (VEGF) and tumour necrosis factor-inducible gene 6 (TSG-6) protein expressions were determined using the Western blot method. Results: Inflammation, vessel dilatation, and haemorrhages were significantly lower in the CAPE group as compared with these parameters in the other groups (P < 0.05). Fibrosis was significantly higher in the ABS group as compared with that in the other groups (P < 0.05). VEGF protein levels were elevated in the 21-day CAPE group and 7-day ABS group. The expression of TSG-6 increased in the 7-day CAPE group and 21-day ABS group. Conclusion: Based on our findings, ABS and CAPE had positive effects on the oral wound healing process.
This study aimed to investigate the presence of asprosin hormone in the biological fluids of patients with periodontal inflammation and compare it to those with periodontal healthy. Seventy-five individuals between the ages of 18 to 45, 25 periodontal healthy, 25 with gingivitis, and 25 with periodontitis, were included in the study. Gingival crevicular fluid (GCF), blood serum and saliva were obtained from individuals in each group. Tumour necrosis factor-alpha (TNF-α) and asprosin levels in these fluids were determined using the ELISA. Clinical periodontal measurements were recorded and body mass index was calculated. One-way ANOVA and Bonferroni tests were performed for statistical analysis. Spearman test was used to evaluate correlations. The significance level was determined as p < 0.05. Body mass index values were not different between the groups (p = 0.446). Clinical periodontal measurements were significantly higher in the periodontitis group. Concentrations of TNF-α in GCF, serum and saliva increased significantly in patients with gingivitis and periodontitis (p < 0.001). The higher TNF-α levels were obtained in patients with periodontitis than in individuals with gingivitis (p = 0.001). While asprosin levels were found to be significantly higher in patients with gingivitis and periodontitis (p < 0.001), no significant difference was observed between both groups (p > 0.05). GCF-asprosin levels were positively correlated with the concentrations in serum and saliva in all individuals included in the study (p < 0.05). The periodontal inflammation caused an increase in asprosin hormone in gingival crevicular fluid independently of the type of periodontal disease. This study is registered with number of “NCT06627972” in ClinicalTrials.gov website from the date of October 3, 2024.